Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a ...
Vorasidenib and ivosidenib inhibit mutant forms of isocitrate dehydrogenase (mIDH) and have shown preliminary clinical activity against mIDH glioma. We evaluated both agents in a perioperative phase …
Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
Jun 12, 2020 · Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated …
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2–4 ...
Dec 19, 2024 · Mutant isocitrate dehydrogenase (IDHm) inhibitors represent a novel targeted approach for treating IDHm glioma patients, yet their optimal use in clinical practice outside of clinical trials …
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Jun 4, 2023 · Mellinghoff IK, Lu M, Wen PY, et al. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med 2023;29:615-622.
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a
Feb 23, 2023 · The dual IDH1/IDH2 inhibitor vorasidenib exhibited better brain permeability and target engagement than ivosidenib in a pilot perioperative randomized clinical trial in patients with IDH1 …
Based on current evidence, ivosidenib for the treatment of IDH mutant glioma has Level 3 (low strength/quality) evidence supporting its use.10002,10003,10004,10005 Currently available data …
Retrospective study of ivosidenib for patients with recurrent IDH ...
May 29, 2024 · Ivosidenib (AG-120), a second-generation IDH inhibitor, is an FDA approved medication for treatment of IDH-mutated acute myeloid leukemia and has demonstrated safety and clinical …
Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
The use of ivosidenib in this study was associated with prolonged tumor control and tumor shrinkage in the patients with advanced glioma [33]. Pharmacokinetic and pharmacodynamic data from this study …
Ivosidenib (Tibsovo®) for Brain Cancer | ChemoExperts
Gliomas are classified into four grades (I, II, III, and IV), of which grade I and II are considered to be low-grade. How does ivosidenib (Tibsovo®) work? Proteins known as I socitrate D e H ydrogenase- 1 …
Treatment of IDH-mutant glioma in the INDIGO era - Nature
Jul 19, 2024 · Ivosidenib, a selective mIDH1 inhibitor, was tested in a phase I trial that enrolled IDH1-mutant glioma patients who had recurred or not responded to standard-of-care therapy 32.